Related references
Note: Only part of the references are listed.Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials
David H. Alpers et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2023)
Preclinical Pharmacokinetic Studies of a Novel Diuretic Inhibiting Urea Transporters
Yue Xu et al.
MOLECULES (2022)
Liver cirrhosis: An overview of experimental models in rodents
Lanuza A. P. Faccioli et al.
LIFE SCIENCES (2022)
Physical and Mental Quality of Life in Patients With End-Stage Liver Disease and Their Informal Caregivers
Lissi Hansen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Discovery of novel diarylamides as orally active diuretics targeting urea transporters
Shun Zhang et al.
ACTA PHARMACEUTICA SINICA B (2021)
N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties
Shuyuan Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Urea Transporters Identified as Novel Diuretic Drug Targets
Min Li et al.
CURRENT DRUG TARGETS (2020)
Optimal management of ascites
Marika Rudler et al.
LIVER INTERNATIONAL (2020)
Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver
Rishabh Sehgal et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
The urea transporter UT-A1 plays a predominant role in a urea-dependent urine-concentrating mechanism
Xiaoqiang Geng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors
Yan Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Generation and phenotypic analysis of mice lacking all urea transporters
Tao Jiang et al.
KIDNEY INTERNATIONAL (2017)
Ascites, refractory ascites and hyponatremia in cirrhosis
Brett Fortune et al.
GASTROENTEROLOGY REPORT (2017)
Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Furosemide and Hydrochlorothiazide Followed by Furosemide for the Treatment of Adults With Nephrotic Edema: A Randomized Trial
Mohammad Amin Fallahzadeh et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment
Keita Hirai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Comparison of TGF-β, PDGF, and CTGF in hepatic fibrosis models using DMN, CCl4, and TAA
Hye-Jung Park et al.
DRUG AND CHEMICAL TOXICOLOGY (2016)
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins et al.
DRUG SAFETY (2015)
Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study
Filippo Morando et al.
LIVER INTERNATIONAL (2015)
Developing Hypothetical Inhibition Mechanism of Novel Urea Transporter B Inhibitor
Min Li et al.
SCIENTIFIC REPORTS (2014)
Thienoquinolins exert diuresis by strongly inhibiting UT-A urea transporters
Huiwen Ren et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Tolvaptan, an orally active non-peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury
Toshiki Miyazaki et al.
HEPATOLOGY RESEARCH (2013)
A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic
Fei Li et al.
KIDNEY INTERNATIONAL (2013)
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis
Andres Cardenas et al.
JOURNAL OF HEPATOLOGY (2012)
Urea transporter physiology studied in knockout mice
Xuechen Li et al.
FRONTIERS IN PHYSIOLOGY (2012)
Role of thin descending limb urea transport in renal urea handling and the urine concentrating mechanism
Tianluo Lei et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites
A. Krag et al.
GUT (2010)
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis
Florence Wong et al.
JOURNAL OF HEPATOLOGY (2010)
Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats
Othman A. Al-Shabanah et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Management of Adult Patients with Ascites Due to Cirrhosis: An Update
Bruce A. Runyon
HEPATOLOGY (2009)
Circulatory function and hepatorenal syndrome in cirrhosis
L Ruiz-del-Arbol et al.
HEPATOLOGY (2005)
Urea and urine concentrating ability: new insights from studies in mice
BX Yang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Lack of UT-B in vasa recta and red blood cells prevents urea-induced improvement of urinary concentrating ability
L Bankir et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2004)
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis.: A randomized comparative study of efficacy and safety
J Santos et al.
JOURNAL OF HEPATOLOGY (2003)
Urea-selective concentrating defect in transgenic mice lacking urea transporter UT-B
B Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
